Singapore, Sept. 16 -- GSK plc has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences, a China-based biotechnology company. GSK plans to develop and commercialise the asset for multiple myeloma, with the programme expected to enter phase I trials in 2027.

Published by HT Digital Content Services with permission from BioSpectrum Asia....